Kenvue Inc.
KVUE
Pozycja w akcjach
#662
Kenvue Inc. functions as a global leader in the consumer health sector. The... Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Cena akcji
$19.29
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$37.05B
Zmiana (1 dzień)
2.23%
Zmiana (1 rok)
29.20%
Kraj
US
Handel Kenvue Inc. (KVUE)
Kategoria
Consumer Defensive
Zyski dla Kenvue Inc. (KVUE)
Zyski w Jun 2026 TTM: $2.22B
Według najnowszych raportów finansowych Kenvue Inc., obecny zysk firmy wynosi $2.22B. W roku 2023 firma osiągnęła zysk w wysokości $2.19B, spadek w porównaniu do zysku z roku 2022, który wynosił $2.64B. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Kenvue Inc. od 2019 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $2.22B | 57.10% |
| 2024 | $1.42B | -35.39% |
| 2023 | $2.19B | -16.95% |
| 2022 | $2.64B | -9.85% |
| 2021 | $2.93B | -387.89% |
| 2020 | $-1.02B | -147.92% |
| 2019 | $2.12B | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $20.38B | 816.64% |
US
|
|
| $9.83B | 342.03% |
FR
|
|
| $2.94B | 32.30% |
US
|
|
| $1.55B | -30.27% |
IN
|
|
| $517.00M | -76.74% |
US
|
